Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Celtaxsys To Hash Out Phase III Cystic Fibrosis Endpoints With US FDA

Executive Summary

Private start-up's acebilustat failed to improve lung function in Phase II, but the anti-inflammatory showed large numerical reductions in pulmonary exacerbations, which can be fatal.

You may also be interested in...



Vertex Cystic Fibrosis Forecast Brightens, With Gloomy Prospects For Competition

Vertex continued its growth story in cystic fibrosis during 2017. It also chose a pair of candidates for Phase III triple combination development, threatening to virtually seal off market entry to others.

Vertex Looks To Triple Combos For CF After Doublet Success

Top-line results from two Phase III studies indicate Vertex’s potential new combination cystic fibrosis therapy, tezacaftor plus ivacaftor, is effective and well tolerated in certain cystic fibrosis patients, and could become the backbone of a triple combination therapy for a wider patient group.

Orkambi Efficacy Sways FDA Panel Despite Uncertainty Over Lumacaftor’s Role

Pulmonary-allergy drugs panel endorses approval of Vertex’s lumacaftor/ivacaftor fixed-dose combination for cystic fibrosis and suggests the question of whether the combination would be more or less effective than ivacaftor monotherapy is not relevant.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS123621

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel